Marker Therapeutics (MRKR) 10-Q 7 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 02, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Entity Registrant Name	TAPIMMUNE INC.
Entity Central Index Key	1,094,038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	TPIV
Entity Common Stock, Shares Outstanding		10,158,993

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 9,962,615	$ 7,851,243
Prepaid expenses and deposits	179,181	70,149
Total current assets	10,141,796	7,921,392
Total assets	10,141,796	7,921,392
Current liabilities:
Accounts payable and accrued liabilities	1,561,075	1,224,940
Research agreement obligations	0	492,365
Warrant liability	10,000	14,500
Promissory note	5,000	5,000
Total current liabilities	1,576,075	1,736,805
Total liabilities	1,576,075	1,736,805
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Common stock, $0.001 par value, 41,666,667 shares authorized, 10,158,993 and 8,421,185 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	10,159	8,421
Additional paid-in capital	159,306,674	151,991,974
Accumulated deficit	(150,751,112)	(145,815,808)
Total stockholders' equity	8,565,721	6,184,587
Total liabilities and stockholders' equity	10,141,796	7,921,392
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	0	0
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	41,666,667	41,666,667
Common stock shares issued	10,158,993	8,421,185
Common stock shares outstanding	10,158,993	8,421,185
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating expenses:
Research and development	$ 1,202,725	$ 1,248,165	$ 2,191,817	$ 2,233,916
General and administrative	1,190,517	1,177,408	2,618,310	1,945,396
Total operating expenses	2,393,242	2,425,573	4,810,127	4,179,312
Loss from operations	(2,393,242)	(2,425,573)	(4,810,127)	(4,179,312)
Other income (expense):
Change in fair value of warrant liabilities	7,500	8,237,000	4,500	5,241,000
Debt extinguishment gain	492,365	0	492,365	0
Grant income	0	231,200	0	231,200
Shares issued in debt settlement agreements	0	(70,315)	0	(70,315)
Other income	0	1,828	0	1,828
Net (loss) income	$ (1,893,377)	$ 5,974,140	$ (4,313,262)	$ 1,224,401
Basic net (loss) income per share	$ (0.22)	$ 1.01	$ (0.51)	$ 0.21
Diluted net (loss) income per share	$ (0.22)	$ 0.35	$ (0.51)	$ (0.19)
Weighted average number of common shares outstanding, basic	8,576,634	5,935,000	8,503,521	5,908,917
Weighted average number of common shares outstanding, diluted	8,576,634	6,524,750	8,503,521	6,652,417

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2017 - USD ($)	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance, Amount at Dec. 31, 2016	$ 6,184,587	$ 8,421	$ 151,991,974	$ (145,815,808)
Beginning Balance, Share at Dec. 31, 2016		8,421,185
Common stock and warrants issued in private placement, Amount	6,190,003	$ 1,504	6,188,499	0
Common stock and warrants issued in private placement, Share		1,503,567
Fees and legal costs relating to private placement	(781,660)	$ 0	(781,660)	0
Exercise of warrants, Amount	666,666	$ 168	666,498	0
Exercise of warrants, Share		167,926
Legal costs relating to exercise of warrants	(28,000)	$ 0	(28,000)	0
Fair value of repriced warrants as inducement	0	0	622,042	(622,042)
Stock-based compensation, Amount	647,387	$ 66	647,321	0
Stock-based compensation, Share		66,315
Net loss	(4,313,262)	$ 0	0	(4,313,262)
Ending Balance, Amount at Jun. 30, 2017	$ 8,565,721	$ 10,159	$ 159,306,674	$ (150,751,112)
Ending Balance, Share at Jun. 30, 2017		10,158,993

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows from Operating Activities:
Net (loss) income	$ (4,313,262)	$ 1,224,401
Reconciliation of net (loss) income to net cash used in operating activities:
Changes in fair value of warrant liabilities	(4,500)	(5,241,000)
Shares issued in debt settlement agreements	0	70,315
Stock-based compensation	647,387	544,934
Debt extinguishment gain	(492,365)	0
Changes in operating assets and liabilities:
Prepaid expenses and deposits	(109,032)	47,409
Accounts payable and accrued expenses	336,135	570,033
Net cash used in operating activities	(3,935,637)	(2,783,908)
Cash Flows from Financing Activities:
Repayment of promissory note	0	(25,000)
Proceeds from issuance of common stock and warrants in private placement, net of offering costs	5,408,343	0
Proceeds from exercise of stock warrants, net of offering costs	638,666	0
Net cash provided by (used in) financing activities	6,047,009	(25,000)
Net increase (decrease) in cash	2,111,372	(2,808,908)
Cash at beginning of period	7,851,243	6,576,564
Cash at end of period	9,962,615	3,767,656
Supplemental schedule of non-cash financing activities:
Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson’s compensation	0	191,000
Fair value of repriced warrants as inducement	$ 622,042	$ 0

NATURE OF OPERATIONS

NATURE OF OPERATIONS	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	Note 1: Nature of Operations TapImmune Inc. (the “Company” or “we”), a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2: Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results. The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2017 or for any future interim period. The condensed consolidated balance sheet at June 30, 2017 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2016, and notes thereto included in the Company’s annual report on Form 10-K filed on March 14, 2017.

LIQUIDITY AND FINANCIAL CONDITI

LIQUIDITY AND FINANCIAL CONDITION	6 Months Ended
	Jun. 30, 2017
Text Block [Abstract]
LIQUIDITY AND FINANCIAL CONDITION	NOTE 3: LIQUIDITY AND FINANCIAL CONDITION The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings and warrant exercises. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales. As of June 30, 2017, the Company had cash of $ 9,963,000

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 4: SIGNIFICANT ACCOUNTING POLICIES There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on March 14, 2017. From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption. Accounting for Certain Financial Instruments with Down Round Features On July 13, 2017, the FASB has issued a two-part Accounting Standards Update (“ASU”), No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures. Compensation-Stock Compensation In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact.

NET (LOSS) INCOME PER SHARE

NET (LOSS) INCOME PER SHARE	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
NET INCOME (LOSS) PER SHARE	Note 5: NET (LOSS) InCOME PER SHARE Basic (loss) income per common share is computed by dividing net (loss) income by the weighted average number of common shares outstanding during the reporting period. Diluted income per common share is computed similar to basic income per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Income (loss) per-share amounts for all prior periods have been retroactively adjusted to reflect the Company’s 1-for-12 reverse stock split, which was effective September 16, 2016. Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Numerator: Net (loss) income $ (1,893,377) $ 5,974,140 $ (4,313,262) $ 1,224,401 Less: non-cash income from change in fair value of common stock warrants - 3,697,000 - 2,492,000 Net (loss) income - diluted (1,893,377) 2,277,140 (4,313,262) (1,267,599) Denominator: Weighted average common shares outstanding - basic 8,576,634 5,935,000 8,503,521 5,908,917 Dilutive effect of warrants, net - 565,417 - 743,500 Dilutive effect of stock options, net - 24,333 - - Weighted average common shares outstanding - diluted 8,576,634 6,524,750 8,503,521 6,652,417 Net (loss) income per share data: Basic $ (0.22) $ 1.01 $ (0.51) $ 0.21 Diluted $ (0.22) $ 0.35 $ (0.51) $ (0.19) Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Common stock options 455,000 251,000 455,000 297,000 Common stock warrants - equity treatment 6,540,000 213,000 6,540,000 213,000 Common stock warrants - liability treatment 3,500 2,283,000 3,500 2,068,000 Potentially dilutive securities 6,998,500 2,747,000 6,998,500 2,578,000

RESEARCH AGREEMENT OBLIGATIONS

RESEARCH AGREEMENT OBLIGATIONS	6 Months Ended
	Jun. 30, 2017
Research and Development [Abstract]
RESEARCH AGREEMENT OBLIGATIONS	Note 6: Research Agreement OBLIGATIONS Crucell Holland B. V. (“Crucell”) – Research License and Option Agreement In 2003 and further amended in 2008, the Company acquired a research license and option agreement from Crucell Holland B.V. for use of an adenovirus technology. The Company has not made use of the technology in its current work and has not asked for nor received any work product from Crucell. Crucell was acquired by Johnson and Johnson in 2010. As of December 31, 2016, the Company had accrued $ 492,365 Upon further legal review and analysis of the agreement undertaken during the quarter, the Company concluded that the statute of limitations has run out on the obligation, and a legal opinion received by the Company confirms the amounts are not currently owed. As such, as of June 30, 2017, the Company was no longer obligated to make the payments under the agreement and therefore, the Company recorded a debt extinguishment gain of $ 492,365 0

WARRANT LIABILITY AND FAIR VALU

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2017
Derivatives and Fair Value [Abstract]
WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS	Note 7: WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS Six Months Ended June 30, 2017 2016 Stock price $ 3.88 $ 6.12 Exercise price $ 1.20 $ 1.20 - $300.00 Contractual term (years) 1.03 0.28 - 4.20 Volatility (annual) 78 % 68% - 151 % Risk-free rate 1.00 % 1.00 % Dividend yield (per share) 0 % 0 % The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations. Financial Liabilities Measured at Fair Value on a Recurring Basis Fair value measured at June 30, 2017 Quoted prices in active Significant other Significant markets observable inputs unobservable inputs Fair value at (Level 1) (Level 2) (Level 3) June 30, 2017 Warrant liability $ - $ - $ 10,000 $ 10,000 Fair value measured at December 31, 2016 Quoted prices in active Significant other Significant markets observable inputs unobservable inputs Fair value at (Level 1) (Level 2) (Level 3) December 31, 2016 Warrant liability $ - $ - $ 14,500 $ 14,500 The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows: ⋅ Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets; ⋅ Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and ⋅ Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions. There were no transfers between Level 1, 2 or 3 during the six months ended June 30, 2017. Warrant Liability Balance - December 31, 2016 $ 14,500 Change in fair value of warrant liability (4,500) Balance – June 30, 2017 $ 10,000

PROMISSORY NOTE

PROMISSORY NOTE	6 Months Ended
	Jun. 30, 2017
Promissory Notes [Abstract]
PROMISSORY NOTES	Note 8: Promissory note At June 30, 2017 and December 31, 2016, the Company had an outstanding promissory note in the amount of $ 5,000 10

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY	Note 9: STOCKHOLDERS’ EQUITY Reverse Stock Split On September 16, 2016, the Company effected a one for twelve reverse stock-split of our issued and outstanding common stock and has retroactively adjusted our common shares outstanding, options and warrants amounts outstanding. The Company has presented its share data for and as of all periods presented on this basis. The par value was not adjusted as a result of the one for twelve reverse stock split. All prior period share transactions included in the Company’s stock transactions and balances have been retroactively restated. 2017 Common Stock Transactions June 2017 Private Placement Transaction On June 26, 2017, the Company completed private placement of units with certain accredited investors. In the private placement transaction, the Company sold 1,503,567 3.97 3.97 0.125 4.095 1,503,567 6.2 0.8 653,187 6.00 In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 150,357 3.97 Pursuant to a Registration Rights Agreement to be entered into at the closing of the private placement offering, promptly, but no later than 90 calendar days after the closing of the offering, the Company is required to file a registration statement with the Securities and Exchange Commission registering for resale (a) the common stock issued in the offering; (b) the shares of common stock issuable upon the exercise of the private placement warrants; and (c) the shares of common stock issuable upon the exercise of the warrants issued to Katalyst Securities LLC, which acted as placement agent for the offering. The Company is required to use its commercially reasonable efforts to ensure that the Registration Statement is declared effective within 90 calendar days after filing with the Securities and Exchange Commission, on or before December 23, 2017. In accordance with the registration rights agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages. The liquidated damages shall be a cash sum payment calculated at a rate of ten percent ( 10 In accordance with U.S. GAAP, a contingent obligation to make future payments must be recorded if the transfer of consideration under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be required to record would be approximately $ 57,000 At the June 26, 2017 private placement closing, and on June 30, 2017, the Company concluded that it is not probable that it will be required to remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness. June 2017 Exercise and Repricing of Warrants Held by Existing Institutional Investors On June 23, 2017, certain existing institutional shareholders of the Company who hold various outstanding warrants (i.e. C, D, E and F) to purchase Company common stock, entered into warrant repricing and exercise agreements. Series E repriced and exercised warrants Approximately 168,000 15.00 3.97 0.7 187,000 4.50 Series C, D & F repriced warrants Series Number of Warrant Shares Repriced Pre-reduced Price Post-reduced Price Series C 313,750 $ 6.00 $ 4.00 Series D 312,500 $ 9.00 $ 4.00 Series F 292,500 $ 7.20 $ 4.00 The fair value relating to the modification of exercise prices on all of the repriced warrants was treated as deemed dividend on the statement of stockholders’ equity of $ 622,000 Weighted Average Inputs Before Modification After Modification Exercise price $ 8.32 $ 4.04 Contractual term (years) 3.34 3.34 Volatility (annual) 200 % 200 % Risk-free rate 1.50 % 1.50 % Dividend yield (per share) 0.00 % 0.00 % 2017 Management Compensation On March 9, 2017, the Company issued 12,761 55,000 4.31 On March 9, 2017, the Company issued 5,220 22,500 4.31 Consulting Arrangements During the six months ended June 30, 2017, the Company issued 48,334 205,000

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	Note 10: STOCK-BASED COMPENSATION The Company recorded $ 271,000 331,000 647,000 545,000 At June 30, 2017, the total stock-based compensation cost related to unvested awards not yet recognized was $ 680,000 0.68 Future option grants will impact the compensation expense recognized.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENT	Note 11: SUBSEQUENT EVENT On July 6, 2017, the Board of Directors of the Company approved the 2017 bonus program for Dr. Glynn Wilson, our Chief Executive Officer and President, and Mr. Michael J. Loiacono, our Chief Financial Officer, Treasurer and Secretary, as recommended by the Compensation Committee of the Board of Directors. Under such bonus program, Dr. Wilson and Mr. Loiacono are eligible for bonuses of up to $ 140,000 60,000 50 30 (i) up to 40% of the bonus amount for meeting scientific, technical and clinical objectives; (ii) up to 20% of the bonus amount for financial performance and corporate objectives related to our raising capital; and (iii) up to 40% of the bonus amount designated to be discretionary as determined by the Board. In order for Dr. Wilson to achieve his eligible bonus of $140,000, he would need 100% attainment in each of the above objectives (i) up to 33.3% of the bonus amount for meeting corporate and operational objectives; (ii) up to 33.3% of the bonus amount for financial performance objectives including related to our raising capital; and (iii) up to 33.3% of the bonus amount designated to be discretionary as determined by the Board. In order for Mr. Loiacono to achieve his eligible bonus of $60,000, he would need 100% attainment in each of the above objectives. The bonuses will be paid in a combination of cash and common stock at the discretion of the Compensation Committee.

SIGNIFICANT ACCOUNTING POLICI18

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncement From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption. Accounting for Certain Financial Instruments with Down Round Features On July 13, 2017, the FASB has issued a two-part Accounting Standards Update (“ASU”), No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures. Compensation-Stock Compensation In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact.

NET (LOSS) INCOME PER SHARE (Ta

NET (LOSS) INCOME PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of net loss per share: Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Numerator: Net (loss) income $ (1,893,377) $ 5,974,140 $ (4,313,262) $ 1,224,401 Less: non-cash income from change in fair value of common stock warrants - 3,697,000 - 2,492,000 Net (loss) income - diluted (1,893,377) 2,277,140 (4,313,262) (1,267,599) Denominator: Weighted average common shares outstanding - basic 8,576,634 5,935,000 8,503,521 5,908,917 Dilutive effect of warrants, net - 565,417 - 743,500 Dilutive effect of stock options, net - 24,333 - - Weighted average common shares outstanding - diluted 8,576,634 6,524,750 8,503,521 6,652,417 Net (loss) income per share data: Basic $ (0.22) $ 1.01 $ (0.51) $ 0.21 Diluted $ (0.22) $ 0.35 $ (0.51) $ (0.19)
Net Loss Per Share	The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented: Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Common stock options 455,000 251,000 455,000 297,000 Common stock warrants - equity treatment 6,540,000 213,000 6,540,000 213,000 Common stock warrants - liability treatment 3,500 2,283,000 3,500 2,068,000 Potentially dilutive securities 6,998,500 2,747,000 6,998,500 2,578,000

WARRANT LIABILITY AND FAIR VA20

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2017
Derivatives and Fair Value [Abstract]
Valuation Methodology	A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the six months ended June 30, 2017 and 2016 is as follows: Six Months Ended June 30, 2017 2016 Stock price $ 3.88 $ 6.12 Exercise price $ 1.20 $ 1.20 - $300.00 Contractual term (years) 1.03 0.28 - 4.20 Volatility (annual) 78 % 68% - 151 % Risk-free rate 1.00 % 1.00 % Dividend yield (per share) 0 % 0 %
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability: Fair value measured at June 30, 2017 Quoted prices in active Significant other Significant markets observable inputs unobservable inputs Fair value at (Level 1) (Level 2) (Level 3) June 30, 2017 Warrant liability $ - $ - $ 10,000 $ 10,000 Fair value measured at December 31, 2016 Quoted prices in active Significant other Significant markets observable inputs unobservable inputs Fair value at (Level 1) (Level 2) (Level 3) December 31, 2016 Warrant liability $ - $ - $ 14,500 $ 14,500
Schedule of Changes in Level 3 Liabilities Measured at Fair Value	The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2017: Warrant Liability Balance - December 31, 2016 $ 14,500 Change in fair value of warrant liability (4,500) Balance – June 30, 2017 $ 10,000

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Summary Of Number Of Price-Reduced and Price-Retained Warrants	Series Number of Warrant Shares Repriced Pre-reduced Price Post-reduced Price Series C 313,750 $ 6.00 $ 4.00 Series D 312,500 $ 9.00 $ 4.00 Series F 292,500 $ 7.20 $ 4.00
Valuation Methodology	A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are included in the modification is as follows: Weighted Average Inputs Before Modification After Modification Exercise price $ 8.32 $ 4.04 Contractual term (years) 3.34 3.34 Volatility (annual) 200 % 200 % Risk-free rate 1.50 % 1.50 % Dividend yield (per share) 0.00 % 0.00 %

LIQUIDITY AND FINANCIAL CONDI22

LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail)	Jun. 30, 2017USD ($)
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 9,963,000

NET (LOSS) INCOME PER SHARE - C

NET (LOSS) INCOME PER SHARE - Computation of income (loss) per share (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Numerator:
Net (loss) income	$ (1,893,377)	$ 5,974,140	$ (4,313,262)	$ 1,224,401
Less: non-cash income from change in fair value of common stock warrants	0	3,697,000	0	2,492,000
Net (loss) income - diluted	$ (1,893,377)	$ 2,277,140	$ (4,313,262)	$ (1,267,599)
Denominator:
Weighted average common shares outstanding - basic	8,576,634	5,935,000	8,503,521	5,908,917
Dilutive effect of warrants, net	0	565,417	0	743,500
Dilutive effect of stock options, net	0	24,333	0	0
Weighted average common shares outstanding - diluted	8,576,634	6,524,750	8,503,521	6,652,417
Net (loss) income per share data:
Basic	$ (0.22)	$ 1.01	$ (0.51)	$ 0.21
Diluted	$ (0.22)	$ 0.35	$ (0.51)	$ (0.19)

NET (LOSS) INCOME PER SHARE - P

NET (LOSS) INCOME PER SHARE - Potentially Dilutive Securities (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Common stock options	455,000	251,000	455,000	297,000
Common stock warrants - equity treatment	6,540,000	213,000	6,540,000	213,000
Common stock warrants - liability treatment	3,500	2,283,000	3,500	2,068,000
Potentially dilutive securities	6,998,500	2,747,000	6,998,500	2,578,000

NET (LOSS) INCOME PER SHARE - A

NET (LOSS) INCOME PER SHARE - Additional Information (Detail)	1 Months Ended
	Sep. 16, 2016
Stockholders' Equity, Reverse Stock Split	1-for-12 reverse stock split

RESEARCH AGREEMENT OBLIGATIONS

RESEARCH AGREEMENT OBLIGATIONS - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Gain (Loss) on Extinguishment of Debt	$ 492,365	$ 0	$ 492,365	$ 0
Crucell Holland BV [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accrued Liabilities					$ 492,365
Gain (Loss) on Extinguishment of Debt			492,365
Debt Instrument, Increase (Decrease), Net			$ 0

WARRANT LIABILITY AND FAIR VA27

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] - $ / shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price	$ 3.88	$ 6.12
Exercise price	$ 1.20
Contractual term (years)	1 year 11 days
Volatility (annual)	78.00%
Risk-free rate	1.00%	1.00%
Dividend yield (per share)	0.00%	0.00%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price		$ 300
Contractual term (years)		4 years 2 months 12 days
Volatility (annual)		151.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price		$ 1.20
Contractual term (years)		3 months 11 days
Volatility (annual)		68.00%

WARRANT LIABILITY AND FAIR VA28

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Quoted prices in active markets (Level 1)
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	$ 0	$ 0
Significant other observable inputs (Level 2)
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	0	0
Significant other observable inputs (Level 3)
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	10,000	14,500
Fair Value [Member]
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	$ 10,000	$ 14,500

WARRANT LIABILITY AND FAIR VA29

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)	6 Months Ended
	Jun. 30, 2017USD ($)
Class of Warrant or Right [Line Items]
Balance	$ 14,500
Change in fair value of warrant liability	(4,500)
Balance	$ 10,000

PROMISSORY NOTE - Additional In

PROMISSORY NOTE - Additional Information (Detail) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Outstanding promissory notes	$ 5,000	$ 5,000
Promissory Notes Due in 2012 [Member]
Debt Instrument [Line Items]
Annual interest rate	10.00%

STOCKHOLDERS_ EQUITY - Summary

STOCKHOLDERS’ EQUITY - Summary of number of price-reduced and price-retained warrants (Detail)	Jun. 30, 2017$ / sharesshares
Series C Warrant [Member] | Number of Warrant Shares Repriced [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares | shares	313,750
Series C Warrant [Member] | Pre-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 6
Series C Warrant [Member] | Post-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 4
Series D Warrant [Member] | Number of Warrant Shares Repriced [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares | shares	312,500
Series D Warrant [Member] | Pre-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 9
Series D Warrant [Member] | Post-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 4
Series F Warrant [Member] | Number of Warrant Shares Repriced [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares | shares	292,500
Series F Warrant [Member] | Pre-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 7.20
Series F Warrant [Member] | Post-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 4

STOCKHOLDERS_ EQUITY - Conversi

STOCKHOLDERS’ EQUITY - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member]	6 Months Ended
	Jun. 30, 2017$ / shares
Weighted Average Inputs Before Modification [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 8.32
Contractual term (years)	3 years 4 months 2 days
Volatility (annual)	200.00%
Risk-free rate	1.50%
Dividend yield (per share)	0.00%
Weighted Average Inputs After Modification [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 4.04
Contractual term (years)	3 years 4 months 2 days
Volatility (annual)	200.00%
Risk-free rate	1.50%
Dividend yield (per share)	0.00%

STOCKHOLDERS_ EQUITY - Addition

STOCKHOLDERS’ EQUITY - Additional Information (Detail)	Mar. 09, 2017USD ($)$ / sharesshares	Jun. 26, 2017USD ($)$ / shares$ / Warrantshares	Jun. 23, 2017USD ($)$ / sharesshares	Jun. 30, 2017USD ($)shares	Jun. 30, 2016USD ($)$ / shares	Aug. 31, 2016$ / shares
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Proceeds from Warrant Exercises				$ 638,666	$ 0
Loss Contingency, Damages Sought, Value		$ 57,000
Adjustments to Additional Paid in Capital, Warrant Issued				$ 0
Series E Warrant [Member] | Class of Warrant or Right,Tranche One [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 15
Series E Warrant [Member] | Class of Warrant or Right,Tranche Two [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			4.50
Subsequent Warrant Issuance [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 3.97
Class Of Warrant Or Right Expiration Period		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		150,357
Liquidated Damages on Aggregate Purchase Price for Registrable Securities		10.00%
Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares				66,315
Adjustments to Additional Paid in Capital, Warrant Issued				$ 0
Additional Paid-in Capital [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued				622,042
Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 3.97				$ 6
Class Of Warrant Or Right Expiration Period		5 years
Legal Fees		$ 800,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		653,187
Equity Unit Issued Price Per Unit | $ / Warrant		4.095
Class of Warrant or Right, Warrant Price | $ / Warrant		0.125
Proceeds from Issuance of Common Stock		$ 6,200,000
Number Of Units Sold | shares		1,503,567
Private Placement [Member] | Series E Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 15		$ 3.97
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			168,000
Proceeds from Warrant Exercises			$ 700,000
Private Placement [Member] | Series E Warrant [Member] | Class of Warrant or Right,Tranche One [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			187,000
Private Placement [Member] | Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Value, New Issues		$ 1,503,567
Shares Issued, Price Per Share | $ / shares		$ 3.97
Consulting Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock				$ 205,000
Common shares issued | shares				48,334
Chief Executive Officer, President and Chairman [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	12,761
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 55,000
Share Price | $ / shares	$ 4.31
President and Chief Operating Officer [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	5,220
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 22,500
Share Price | $ / shares	$ 4.31

STOCK-BASED COMPENSATION - Addi

STOCK-BASED COMPENSATION - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation	$ 271,000	$ 331,000	$ 647,387	$ 544,934
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 680,000		$ 680,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			8 months 5 days

SUBSEQUENT EVENT - Additional I

SUBSEQUENT EVENT - Additional Information (Detail) - Subsequent Event [Member]	Jul. 06, 2017USD ($)
Chief Financial Officer, Treasurer and Secretary [Member]
Subsequent Event [Line Items]
Bonus Payable, Description	The bonus amount of up to $60,000 to Mr. Loiacono is to be allocated upon the achievement of the following objectives: (i) up to 33.3% of the bonus amount for meeting corporate and operational objectives; (ii) up to 33.3% of the bonus amount for financial performance objectives including related to our raising capital; and (iii) up to 33.3% of the bonus amount designated to be discretionary as determined by the Board. In order for Mr. Loiacono to achieve his eligible bonus of $60,000, he would need 100% attainment in each of the above objectives.
Chief Financial Officer, Treasurer and Secretary [Member] | Maximum [Member]
Subsequent Event [Line Items]
Bonus on Base Salaries, Percentage	30.00%
Officers' Compensation	$ 60,000
Chief Executive Officer and President [Member]
Subsequent Event [Line Items]
Bonus Payable, Description	The bonus amount of up to $140,000 to Dr. Wilson is to be allocated upon the achievement of the following objectives: (i) up to 40% of the bonus amount for meeting scientific, technical and clinical objectives; (ii) up to 20% of the bonus amount for financial performance and corporate objectives related to our raising capital; and (iii) up to 40% of the bonus amount designated to be discretionary as determined by the Board. In order for Dr. Wilson to achieve his eligible bonus of $140,000, he would need 100% attainment in each of the above objectives.
Chief Executive Officer and President [Member] | Maximum [Member]
Subsequent Event [Line Items]
Bonus on Base Salaries, Percentage	50.00%
Officers' Compensation	$ 140,000